|
|
|
Insider
Information: |
Shah Rajeev M. |
Relationship: |
10% Owner |
City: |
Boston |
State: |
MA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
49 |
|
Direct
Shares |
20,000 |
|
Indirect Shares
|
279,677,593 |
|
|
Direct
Value |
$134,400 |
|
|
Indirect Value
|
$1,656,812,165 |
|
|
Total
Shares |
279,697,593 |
|
|
Total
Value |
$1,656,946,565 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
40
|
13
|
Stock
price went up :
|
20
|
8
|
Stock
price went down : |
20
|
5
|
|
|
|
Gain/Loss Ratio : |
0.0
|
1.6
|
Percentage
Gain/Loss : |
10.4%
|
-60.6%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Ra Pharmaceuticals, Inc. |
RARX |
Director, 10% Owner |
2016-10-31 |
0 |
2020-04-02 |
0 |
Premium* |
|
Kalvista Pharmaceuticals Inc |
KALV |
Director, 10% Owner |
2016-11-21 |
0 |
2017-10-12 |
1,441,070 |
Premium* |
|
Kala Pharmaceuticals, Inc. |
KALA |
10% Owner |
2021-06-17 |
20,000 |
2022-05-26 |
7,039,613 |
Premium* |
|
Solid Biosciences Inc |
SLDB |
Director, 10% Owner |
2018-01-30 |
0 |
2022-12-02 |
109,661 |
Premium* |
|
Eidos Therapeutics, Inc. |
EIDX |
Director |
2018-06-22 |
0 |
2018-06-22 |
2,162,671 |
Premium* |
|
Satsuma Pharmaceuticals, Inc. |
STSA |
Director, 10% Owner |
2019-09-17 |
0 |
2023-06-06 |
0 |
Premium* |
|
Phathom Pharmaceuticals, Inc. |
PHAT |
10% Owner |
|
0 |
2021-03-11 |
3,115,008 |
Premium* |
|
89bio, Inc. |
ETNB |
Director, 10% Owner |
2019-11-11 |
0 |
2024-04-11 |
14,175,398 |
Premium* |
|
Synthorx, Inc. |
THOR |
10% Owner |
2020-01-23 |
0 |
2020-01-23 |
0 |
Premium* |
|
Black Diamond Therapeutics, Inc. |
BDTX |
Director |
2021-05-20 |
0 |
2023-07-05 |
3,525,754 |
Premium* |
|
Scpharmaceuticals Inc. |
SCPH |
10% Owner |
2020-02-14 |
0 |
2021-03-15 |
2,727,446 |
Premium* |
|
Verastem, Inc. |
VSTM |
10% Owner |
|
0 |
2020-06-25 |
16,142,051 |
Premium* |
|
Enliven Therapeutics Ord Shs |
ELVN |
Former 10% owner |
2020-03-16 |
0 |
2023-02-23 |
2,122,465 |
Premium* |
|
TG Therapeutics Inc |
TGTX |
10% Owner |
|
0 |
2020-09-09 |
12,629,868 |
Premium* |
|
Vaxcyte, Inc. |
PCVX |
10% Owner |
|
0 |
2020-10-08 |
5,001,593 |
Premium* |
|
Forma Therapeutics Holdings, Inc., |
FMTX |
10% Owner |
2020-06-23 |
0 |
2022-10-14 |
0 |
Premium* |
|
Rhythm Pharmaceuticals, Inc. |
RYTM |
10% Owner |
2020-06-25 |
0 |
2020-07-02 |
5,140,408 |
Premium* |
|
Akouos, Inc. |
AKUS |
10% Owner |
2020-06-30 |
0 |
2020-06-30 |
2,281,249 |
Premium* |
|
Nkarta, Inc. |
NKTX |
Director, 10% Owner |
2020-07-14 |
0 |
2024-03-27 |
10,805,129 |
Premium* |
|
Pandion Therapeutics, Inc. |
PAND |
10% Owner |
2020-07-21 |
0 |
2020-07-21 |
1,770,023 |
Premium* |
|
Inozyme Pharma, Inc. |
INZY |
10% Owner |
2020-07-28 |
0 |
2020-07-28 |
2,003,653 |
Premium* |
|
Iteos Therapeutics, Inc. |
ITOS |
Former 10% Owner |
2020-07-28 |
0 |
2024-05-12 |
3,517,259 |
Premium* |
|
Inhibrx, Inc. |
INBX |
10% Owner |
2020-08-21 |
0 |
2020-08-21 |
2,129,003 |
Premium* |
|
Dyne Therapeutics, Inc. |
DYN |
10% Owner |
2020-09-21 |
0 |
2020-09-21 |
2,805,045 |
Premium* |
|
Pmv Pharmaceuticals, Inc. |
PMVP |
10% Owner |
2020-09-29 |
0 |
2020-09-29 |
1,710,265 |
Premium* |
|
Cardiff Oncology Inc |
CRDF |
10% Owner |
|
0 |
2020-09-30 |
3,290,000 |
Premium* |
|
Orchard Therapeutics Plc |
ORTX |
10% Owner |
2020-08-10 |
0 |
2020-09-24 |
9,880,865 |
Premium* |
|
Viridian Therapeutics Ors Shs |
VRDN |
10% Owner |
|
0 |
2020-12-07 |
410,686 |
Premium* |
|
Iterum Therapeutics Plc |
ITRM |
10% Owner |
2021-02-04 |
0 |
2021-02-04 |
11,651,597 |
Premium* |
|
Vor Biopharma Inc. |
VOR |
Director, 10% Owner |
2021-02-09 |
0 |
2022-12-09 |
22,748,880 |
Premium* |
|
Werewolf Therapeutics, Inc. |
HOWL |
Director, 10% Owner |
2021-05-04 |
0 |
2023-01-06 |
6,144,881 |
Premium* |
|
Aerovate Therapeutics, Inc. |
AVTE |
Director, 10% Owner |
2021-07-02 |
0 |
2021-07-02 |
311,170 |
Premium* |
|
Acumen Pharmaceuticals, Inc. |
ABOS |
Director, 10% Owner |
2021-07-06 |
0 |
2023-07-21 |
14,932,063 |
Premium* |
|
Cytek Biosciences, Inc. |
CTKB |
Director, 10% Owner |
2021-07-27 |
0 |
2022-03-15 |
13,381,054 |
Premium* |
|
Icosavax, Inc. |
ICVX |
Director, 10% Owner |
2021-08-02 |
0 |
2024-02-19 |
0 |
Premium* |
|
Eliem Therapeutics, Inc. |
ELYM |
Director, 10% Owner |
|
0 |
2021-08-12 |
841,087 |
Premium* |
|
Rxsight, Inc. |
RXST |
10% Owner |
|
0 |
2021-08-03 |
3,052,796 |
Premium* |
|
Tyra Biosciences, Inc. |
TYRA |
Director, 10% Owner |
2021-09-17 |
0 |
2024-02-06 |
10,416,609 |
Premium* |
|
Dice Therapeutics, Inc. |
DICE |
Former 10% owners and ... |
2021-09-17 |
0 |
2023-08-09 |
0 |
Premium* |
|
An2 Therapeutics Ord Shs |
ANTX |
10% Owner |
2022-03-29 |
0 |
2023-08-18 |
5,551,295 |
Premium* |
|
Pepgen Inc. |
PEPG |
Director, 10% Owner |
2022-05-10 |
0 |
2024-02-09 |
10,689,545 |
Premium* |
|
Wave Life Sciences Ltd. |
WVE |
Director, 10% Owner |
2022-06-16 |
0 |
2023-12-11 |
18,202,009 |
Premium* |
|
Fulcrum Therapeutics, Inc. |
FULC |
10% Owner |
|
0 |
2023-01-20 |
11,609,704 |
Premium* |
|
Silverback Therapeutics, Inc. |
SBTX |
Director, 10% Owner |
2022-11-08 |
0 |
2024-03-27 |
10,860,977 |
Premium* |
|
Acrivon Therapeutics, Inc. |
ACRV |
Director, 10% Owner |
2022-11-17 |
0 |
2024-04-11 |
8,340,508 |
Premium* |
|
Mineralys Therapeutics, Inc. |
MLYS |
Director |
2023-02-14 |
0 |
2024-02-12 |
4,850,984 |
Premium* |
|
Janux Therapeutics, Inc. |
JANX |
Director, 10% Owner |
2023-07-19 |
0 |
2023-07-19 |
9,165,652 |
Premium* |
|
Lenz Therapeutics |
LENZ |
Director, 10% Owner |
2024-03-21 |
0 |
2024-03-21 |
694,755 |
Premium* |
|
Boundless Bio, Inc. |
BOLD |
10% Owner |
2024-04-02 |
0 |
2024-04-02 |
295,844 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
216 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 3 of 9
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
DICE |
Dice Therapeutics, Inc. |
Director |
|
2021-09-17 |
4 |
B |
$17.00 |
$23,800,000 |
I/I |
1,400,000 |
786,407 |
2.25 |
% |
|
DICE |
Dice Therapeutics, Inc. |
Director |
|
2021-09-17 |
4 |
A |
$0.00 |
$0 |
I/I |
3,808,911 |
708,829 |
0 |
- |
|
DICE |
Dice Therapeutics, Inc. |
Director |
|
2022-10-17 |
4 |
B |
$36.50 |
$59,860,000 |
I/I |
1,640,000 |
6,848,911 |
2.25 |
% |
|
DICE |
Dice Therapeutics, Inc. |
Director |
|
2023-03-23 |
4 |
B |
$26.67 |
$4,136,224 |
I/I |
155,089 |
6,217,593 |
2.25 |
% |
|
DICE |
Dice Therapeutics, Inc. |
Director |
|
2023-03-24 |
4 |
B |
$26.87 |
$5,168,041 |
I/I |
192,335 |
6,409,928 |
2.25 |
% |
|
DICE |
Dice Therapeutics, Inc. |
Director |
|
2023-03-27 |
4 |
B |
$27.48 |
$4,153,107 |
I/I |
151,132 |
6,561,060 |
2.25 |
% |
|
DICE |
Dice Therapeutics, Inc. |
Director |
|
2023-03-28 |
4 |
B |
$29.24 |
$7,215,818 |
I/I |
246,779 |
6,807,839 |
2.25 |
% |
|
DICE |
Dice Therapeutics, Inc. |
Director |
|
2023-03-29 |
4 |
B |
$29.38 |
$1,949,921 |
I/I |
66,369 |
6,874,208 |
2.25 |
% |
|
DICE |
Dice Therapeutics, Inc. |
Director |
|
2023-03-30 |
4 |
B |
$28.74 |
$5,632,954 |
I/I |
195,997 |
7,070,205 |
2.25 |
% |
|
DICE |
Dice Therapeutics, Inc. |
Former 10% owners and Director |
|
2023-08-09 |
4 |
D |
$0.00 |
$0 |
I/I |
(7,856,612) |
0 |
0 |
- |
|
DYN |
Dyne Therapeutics, Inc. |
10% Owner |
|
2020-09-21 |
4 |
B |
$19.00 |
$12,540,000 |
I/I |
660,000 |
2,805,045 |
1.5 |
% |
|
DYN |
Dyne Therapeutics, Inc. |
10% Owner |
|
2020-09-21 |
4 |
A |
$0.00 |
$0 |
I/I |
2,145,045 |
2,145,045 |
0 |
- |
|
EIDX |
Eidos Therapeutics, Inc. |
Director |
|
2018-06-22 |
4 |
B |
$17.00 |
$18,000,008 |
I/I |
1,058,824 |
2,162,671 |
2.1 |
- |
|
EIDX |
Eidos Therapeutics, Inc. |
Director |
|
2018-06-22 |
4 |
A |
$0.00 |
$0 |
I/I |
1,103,847 |
1,103,847 |
0 |
- |
|
ELVN |
Enliven Therapeutics Ord ... |
10% Owner |
|
2020-03-16 |
4 |
B |
$16.00 |
$10,000,000 |
I/I |
625,000 |
1,454,348 |
1.5 |
- |
|
ELVN |
Enliven Therapeutics Ord ... |
10% Owner |
|
2020-03-16 |
4 |
A |
$0.00 |
$0 |
I/I |
829,348 |
829,348 |
0 |
- |
|
ELVN |
Enliven Therapeutics Ord ... |
10% Owner |
|
2022-10-17 |
4 |
B |
$3.36 |
$489,458 |
I/I |
145,672 |
2,774,398 |
1.5 |
- |
|
ELVN |
Enliven Therapeutics Ord ... |
10% Owner |
|
2022-10-17 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,628,726 |
|
- |
|
ELVN |
Enliven Therapeutics Ord ... |
10% Owner |
|
2022-10-18 |
4 |
B |
$3.76 |
$882,844 |
I/I |
234,799 |
3,009,197 |
1.5 |
- |
|
ELVN |
Enliven Therapeutics Ord ... |
10% Owner |
|
2022-10-19 |
4 |
B |
$3.89 |
$488,659 |
I/I |
125,726 |
3,134,923 |
1.5 |
- |
|
ELVN |
Enliven Therapeutics Ord ... |
10% Owner |
|
2022-10-20 |
4 |
B |
$3.95 |
$44,801 |
I/I |
11,342 |
3,146,265 |
1.5 |
- |
|
ELVN |
Enliven Therapeutics Ord ... |
10% Owner |
|
2022-10-21 |
4 |
B |
$3.92 |
$188,552 |
I/I |
48,100 |
3,194,365 |
1.5 |
- |
|
ELVN |
Enliven Therapeutics Ord ... |
10% Owner |
|
2022-10-24 |
4 |
B |
$3.91 |
$103,459 |
I/I |
26,460 |
3,220,825 |
1.5 |
- |
|
ELVN |
Enliven Therapeutics Ord ... |
10% Owner |
|
2022-12-08 |
4 |
B |
$3.75 |
$39,750 |
I/I |
10,600 |
3,231,425 |
1.5 |
- |
|
ELVN |
Enliven Therapeutics Ord ... |
10% Owner |
|
2022-12-09 |
4 |
B |
$3.93 |
$75,845 |
I/I |
19,299 |
3,250,724 |
1.5 |
- |
|
216 Records found
|
|
Page 3 of 9 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|